Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Insomnia
Phase NA
Enrollment 275
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled clinical trial is to assess a novel cognitive-behavioral program for sleep and mental health using a multidomain web platform (eCBTi+) in participants with insomnia and subjective cognitive complaint. The main questions it aims to answer are: * Whether the eCBTi+ intervention improves sleep (subjective: Insomnia severity index \[ISI\], objective: EEG-based sleep efficiency) sleep and mental health (Geriatric Anxiety Index \[GAI\] and Geriatric Depression Scale \[GDS\]) compared to the control intervention * Whether the eCBTi+ intervention improves cognitive abilities (subjective: Cognitive Failure Questionnaire \[CFQ\], objective: CANTAB executive functions composite score) compared to the control intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: cognitive behavioral therapy for sleep, anxiety, and depression — This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
  • Behavioral: education about healthy nutrition habits and communication in older age — This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings

Primary Outcomes

  • Insomnia severity index (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Subjective cognitive impairment based on cognitive failure questionnaire (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Objective cognitive performance based on a composite score for executive functions from the CANTAB (At baseline and at 24 weeks after the start of the intervention)
  • Geriatric anxiety index (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Geriatric depression scale (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-15
Completion: 2026-12
Eligibility
Age: 60 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 275 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Contact Information
Study Contact:
Thien Thanh Dang-Vu, MD PhD
+1 (514) 340-3540
tt.dangvu@concordia.ca
Rebecca Robillard, PhD
+1 (613) 722-6521
rebecca.robillard@uottawa.ca
Rébecca Robillard, PhD
+1 613-722-6521
e-cosmos@uottawa.ca
The Royal's Institute of Mental Health Research (IMHR)
Interventions
  • Behavioral: cognitive behavioral therapy for sleep, anxiety, and depression — This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
  • Behavioral: education about healthy nutrition habits and communication in older age — This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
Study Locations (2 sites)
The Royal's Institute of Mental Health Research (IMHR), Ottawa, Ontario K1Z7K4 Canada
Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de l'Île-de-Montréal. CCSMTL - IUGM, Montreal, Quebec H3W 1W5 Canada
Eligibility Criteria
Inclusion * age 60 years or older at the time of enrolment * Sleep Condition Indicator, SCI ≤ 16 and/or meeting DSM-V criteria based on the symptoms assessed by the SCI * subjective cognitive complaints (self-report version of Everyday Cognition scale (ECog), score ≥ 2 on any item) * ability to read and understand French or English * ability to use a smartphone or tablet, and access to home internet connection * If on hypnotic or psychotropic medication (including cannabis), being on stable dosage for at least 2 months prior to study entry * Score on the STOP-BANG questionnaire \< 3 corresponding to participants with low risk of obstructive sleep apnea Exclusion * located outside of Québec or Ontario * current hospitalization or planned major surgery * uncorrected severe hearing or vision impairment * reported diagnosis of major neurocognitive disorder or mild cognitive impairment (MCI) * performance suggestive of major neurocognitive disorder or MCI on T-MoCA \< 17 * reported diagnosis of schizophrenia or bipolar disorder * reported diagnosis or positive screen on the MINI for psychotic or bipolar disorders * high suicidal risk, as assessed by the modified Columbia-Suicide Severity Rating Scale * reported diagnosis or positive screening (apnea-hypopnea index \>30 on a level 3 home sleep apnea test) for another untreated sleep disorder (e.g., sleep disordered breathing (OSA), REM sleep behavior disorder (RBD), restless legs syndrome (RLS); individuals with treated and controlled OSA (residual apnea-hypopnea index \<30 and good therapeutic compliance) or RLS will not be excluded * current shift work * currently receiving CBT, having received CBTi in the past * frequent alcohol consumption having an impact on functionning (\>10 glasses/week and having a significant impact on functionning) * illicit drugs use (more than once a month) Additional exclusion criteria for neuroimaging * psychotropic (including hypnotic) medication in the past 2 weeks * contraindications for MRI (e.g., pacemaker, metallic implant, claustrophobia) * unable or unwilling to come to one of the participating MRI centers (Montreal, Ottawa) * medical conditions likely to affect sleep; in particular: * current neurological disorder (e.g., epilepsy with any seizure in the past year, concussion in the past 3 months, multiple sclerosis, Parkinson's disease) * past history of brain lesion (e.g., brain hemorrhage, brain tumor, any condition having required brain surgery) * major surgery (i.e., requiring general anesthesia) in the past 3 months * untreated thyroid disorder * chronic pain syndrome self-reported as interfering with sleep (e.g., migraine, fibromyalgia, rheumatoid arthritis) * recent and severe infection in the past 3 months (e.g., pneumonia, kidney infection) * active cancer or treated cancer with post-cancer treatment for less than 2 years Inclusion/exclusion criteria for good sleepers Twenty-five good sleepers without cognitive complaint will be recruited as controls for the MRI session following the same criteria described above, except that SCI ≥ 17, not meeting the diagnostic criteria for chronic insomnia as assessed by the insomnia module of the SCID and no subjective cognitive complaint.
Conditions Schizophrenia and Related Disorders
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active rTMS stimulation — Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
  • Device: Sham rTMS stimulation — Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.

Primary Outcomes

  • Brain connectivity as indicated by resting-state functional connectivity (rsFC) values as assessed by functional MRI (fMRI) (baseline, visit 11 (about 2 week after baseline), visit 21 (about 4 weeks after baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-23
Completion: 2030-06-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Xiaoming Du, PhD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Alina Siatka
713-486-2740
Alina.Siatka@uth.tmc.edu
Xiaoming Du, PhD
443-882-9717
Xiaoming.Du@uth.tmc.edu
Xiaoming Du, PhD
713-486-2700
Xiaoming.Du@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Device: Active rTMS stimulation — Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
  • Device: Sham rTMS stimulation — Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Male and female ages between ages 18-60 years. * Ability to give written informed consent (age 18 or above). * Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10. * Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3. Exclusion Criteria: * Inability to sign informed consent. * Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions. * Significant alcohol or other drug use other than nicotine or marijuana dependence. * Inability to refrain from using alcohol and/or marijuana 24 hours or more prior to experiments. * Pregnancy, as classified by a woman of child-bearing potential who is not using a contraceptive and has missed a menstrual period; or by self-report; or by positive urine pregnancy test. * For MRI, inability to participate in the MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or declining to get in the scanner. * Failed TMS safety questionnaire.
Conditions Major Depression, Pregnancy, Postpartum ...
Phase NA
Enrollment 156
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: active tDCS — 2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
  • Other: workbook — Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
  • Device: sham tDCS — Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks

Primary Outcomes

  • Depressive symptoms post treatment (End of Week 3 of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-08
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women's College Hospital
Collaborators: Centre for Addiction and Mental Health, Sunnybrook Health Sciences Centre
Principal Investigators:
  • Sophie Grigoriadis, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sunnybrook Health Sciences Centre
  • Daniel Blumberger, MD, MSc (PRINCIPAL_INVESTIGATOR) - Centre for Addiction and Mental Health
  • Simone Vigod, MD, MSc (PRINCIPAL_INVESTIGATOR) - Women's College Hospital
Contact Information
Study Contact:
Simone Vigod
4163236400
simone.vigod@wchospital.ca
Sophie Grigoriadis, MD
416-480-5677
sophie.grigoriadis@sunnybrook.ca
Sunnybrook Health Sciences Centre
Sophie Grigoriadis, MD
Sunnybrook Health Sciences Centre
Interventions
  • Device: active tDCS — 2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
  • Other: workbook — Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
  • Device: sham tDCS — Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
Study Locations (2 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Women's College Hospital, Toronto, Ontario M5S1B2 Canada
Eligibility Criteria
Inclusion criteria: 1. Adult, ≥18 years of age 2. Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization 3. In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features) 4. Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use 5. No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment Exclusion criteria: 1. Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS 2. Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 3. Bipolar disorder as assessed by MINI International Neuropsychiatric Interview 4. Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview 5. Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia/eclampsia in current pregnancy or neurologic illness or seizure history 6. Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI/Co-I assessment) 7. Metal implants in cranium or any electrical implants 8. Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS 9. Visibly non-intact skin/rash on scalp areas at stimulation electrode sites 10. Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English
Conditions Glucose Metabolism Disorders (Including ...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study examines the association of variability in glucose values over a 10-day period with cognitive function and functional status among individuals with prediabetes, aged 50 or older.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Interventions / Regimen

  • Device: Continuous Glucose Monitoring System (CGMS) — Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.

Primary Outcomes

  • Aggregate Executive Functioning Score (Day 10)
  • Aggregate Memory Score (Day 10)
  • Aggregate Language Score (Day 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-01
Completion: 2026-12-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Maryland, Baltimore
Collaborators: Baltimore VA Medical Center, University of Maryland, Baltimore County
Principal Investigators:
  • Tasneem Khambaty, PhD (PRINCIPAL_INVESTIGATOR) - University of Maryland, Baltimore County
Contact Information
Study Contact:
Kathleen Simpson
4106057179
Kathleen.Simpson@va.gov
Ashley Splain, BA
asplain1@umbc.edu
Tasneem Khambaty, PhD
410-455-2304
khambaty@umbc.edu
Baltimore VA Geriatric Research Education and Clinical Center (GRECC)
Interventions
  • Device: Continuous Glucose Monitoring System (CGMS) — Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
Study Locations (1 sites)
Baltimore VA Geriatric Research Education and Clinical Center (GRECC), Baltimore, Maryland 21201 United States
Eligibility Criteria
Inclusion Criteria: * Aged 50 years and older * At least 8th grade education Exclusion Criteria: * Diagnosed type 1 or type 2 diabetes * Current use of mediation for diabetes (oral hypoglycemic agents, insulin), or with diabetic properties (e.g., steroids) * Chronic disorders (cardiovascular disease, peripheral vascular disease, stroke, transient ischemic attack, chronic kidney disease, past year cancer) * Neurological disorders (e.g., Parkinson's, epilepsy, multiple sclerosis) * History of dementia or suspected dementia * Known HIV * Serious mental illness, psychosis, or use of psychotropic medication * Heavy alcohol use
Conditions Positive Affect, Depression
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Virtual Reality-Reward Training (VR-RT) — Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
  • Behavioral: Virtual Reality-Memory Training (VR-MT) — Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral non-personal stories

Primary Outcomes

  • The Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Subscale (MASQ-AD) (Change from Week 0 assessment to Post-Assessment (Week 8). Change from Week 0 assessment to Follow-Up (Week 12).)
  • Positive Valence Systems Scale (PVSS-21) (Change from Week 0 assessment to Post-Assessment (Week 8). Change from Week 0 assessment to Follow-Up (Week 12).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-08
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Contact Information
Study Contact:
Aleeza West
‪(323) 508-3571‬
vrtrainingucla@proton.me
University of California, Los Angeles
Michelle Craske, PhD
University of California, Los Angeles
Interventions
  • Behavioral: Virtual Reality-Reward Training (VR-RT) — Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
  • Behavioral: Virtual Reality-Memory Training (VR-MT) — Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral non-personal stories
Study Locations (1 sites)
University of California, Los Angeles, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: 1. At least 18 years old 2. Fluent in written and spoken English 3. Meet all of the following dimensional score cutoffs: 1. Score on the DASS-21 depression subscale must be ≥ 8 2. Score on the PANAS-P of 27 or lower 3. Score on the WSAS of ≥ 11 Exclusion Criteria: 1. Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage 2. Substance use disorder in the past 6 months 3. Current use of psychotropic medications 4. Currently pregnant or planning to become pregnant 5. Self-reported frequent motion sickness 6. Self-reported seizures within the last year and/or a diagnosis of epilepsy
Conditions Depression, Obsessive-Compulsive Disorde...
Phase Not Applicable
Enrollment 156000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Device: NeuroStar Advanced TMS Therapy System — non-invasive brain stimulation device

Primary Outcomes

  • Change in clinical assessment score from baseline to post-treatment (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-25
Completion: 2035-12
Eligibility
Age: 5 Years – 120 Years
Sex: ALL
Volunteers: false
Enrollment: 156000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neuronetics
Principal Investigators:
  • Eleanor Cole, PhD (STUDY_DIRECTOR) - Neuronetics
Contact Information
Study Contact:
Neha Goyal
763-528-1599
neha.goyal@neurostar.com
Eleanor Cole, PhD
415-724-7960
Eleanor.cole@neurostar.com
Eleanor Cole
Neuronetics
Interventions
  • Device: NeuroStar Advanced TMS Therapy System — non-invasive brain stimulation device
Study Locations (1 sites)
Neuronetics, Malvern, Pennsylvania 19355 United States
Eligibility Criteria
Inclusion Criteria: * Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date of November 01, 2008 or later. Exclusion Criteria: • Incomplete information on treatment parameters
Conditions Intracerebral Hemorrhage, Stroke, Hypert...
Phase Not Applicable
Enrollment 1018
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Clevidipine Injection — Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
  • Drug: Alternate IV Antihypertensive Regimen — The alternate IV antihypertensive regimen would be the institutional standard management at designated "non-clevidipine hospitals". It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.

Primary Outcomes

  • Blood Pressure Monitoring (15 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-01
Completion: 2028-07-30
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 1018 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zeenat Qureshi Stroke Institute
Collaborators: Chiesi USA, Inc.
Contact Information
Study Contact:
Jeein Kim
(949) 824-5011
pashmeen.lakhani@zqsi.org
University of California
Sean R. McDougall
University of California
Melody Halio
661-949-5000
pashmeen.lakhani@zqsi.org
Antelope Valley Medical Center
Interventions
  • Drug: Clevidipine Injection — Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
  • Drug: Alternate IV Antihypertensive Regimen — The alternate IV antihypertensive regimen would be the institutional standard management at designated "non-clevidipine hospitals". It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Study Locations (20 sites)
University of California, Irvine, California 92696-7600 United States
Antelope Valley Medical Center, Lancaster, California 93534 United States
Stanford Medical Center (Stanford Health Care), Palo Alto, California 94304 United States
Cleveland Clinic Martin North Hospital, Stuart, Florida 34994 United States
University of South Florida, Tampa, Florida 33606 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Augusta University-Neuroscience Center, Augusta, Georgia 30912 United States
Wellstar Kennestone Regional Medical Center, Marietta, Georgia 30060 United States
Community Hospital, Munster, Indiana 46321 United States
Frederick Memorial Hospital, Frederick, Maryland 21701 United States
Eligibility Criteria
Inclusion Criteria 1. Age 18 years or older and less than 100 years. 2. Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset. 3. Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect. 4. Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater. 5. Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment 6. Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement \>5 cc (excluding microhemorrhages) 7. Admission SBP greater than and equal to 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for exclusion of ICH patients with initial SBP ≥220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP ≥220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days. 8. Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow-up visits. 9. Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA/ASA guidelines. 10. Patients who will undergo surgical evacuation consistent with AHA/ASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery/intervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)/ Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with ≤5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention. 11. Patients requiring external ventricular drainage consistent with AHA/ASA guidelines or local institutional guidelines are eligible. Exclusion Criteria 1. Time of symptom onset cannot be reliably assessed. 2. Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms. 3. Intracerebral hematoma considered to be related to trauma. 4. ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria). 5. Subject considered a candidate for immediate surgical intervention by the neurosurgery service. 6. Pregnancy, parturition within previous 30 days, or active lactation. 7. Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH. 8. Platelet count of less than 50,000/mm3. 9. Known sensitivity to nicardipine or clevidipine. 10. Patient's living will precludes aggressive ICU management. 11. Patients with allergies to soybeans, soy products, eggs, or egg products. 12. Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. 13. Patients with severe aortic stenosis.

'Ai Pono Cooking Demonstrations

NCT06526650
Recruiting
Conditions Type 2 Diabetes, Hypertension, Dyslipide...
Phase NA
Enrollment 1780
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Native Hawaiians' traditional lifestyles and diets ensured the mutual health and well-being of the land and its inhabitants, which stand in stark contrast to the disproportionately high prevalence of diet-related, cardiometabolic diseases they experience today. In this project, the investigators will adapt and test an evidence-based multilevel intervention entitled PILI 'Āina to improve the self-management of prevalent cardiometabolic diseases and reduce risk factors for developing new diet-related illnesses and implement and evaluate the impact and sustainability of community-wide cooking demonstrations. The objectives of this project are to optimize the effectiveness and sustainability of PILI 'Āina, improve diet quality, cardiometabolic markers, promote traditional Native Hawaiian diets, and improve social cohesion.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: 'Ai Pono — "Hands-on Cooking and Cultural Lessons" These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare.

Primary Outcomes

  • Family Environment (Baseline, 1-year, 2-year, 3-year, 4-year)
  • Nutrition Environment (Baseline, 1-year, 2-year, 3-year, 4-year)
  • Social Cohesionn (Baseline, 1-year, 2-year, 3-year, 4-year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-12
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1780 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Hawaii
Collaborators: National Institutes of Health (NIH), American Heart Association, National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Claire Ing, DrPH (PRINCIPAL_INVESTIGATOR) - Principal Investigator
  • Kulani DeSimone, B.S. (STUDY_CHAIR) - Graduate Assistant
Contact Information
Study Contact:
Claire Ing, DrPH
8086921042
clairemt@hawaii.edu
Ki'i Aweau
Meghan Kenney
8085208997
meghan@kula-papakolea.org
Kula no na Poe Hawaii
Interventions
  • Other: 'Ai Pono — "Hands-on Cooking and Cultural Lessons" These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare.
Study Locations (2 sites)
Kula no na Poe Hawaii, Honolulu, Hawaii 96813 United States
Kapolei Community Development Coalition, Kapolei, Hawaii 96707 United States
Eligibility Criteria
Inclusion Criteria: * Age 18+ (looking for older adults) * Native Hawaiian resident in a participating homestead * Overweight or obese (BMI ≥ 25 kg/m\^2) * Prior diagnosis of type 2 diabetes or pre-diabetes, hypertension, and/or dyslipidemia (LDL cholesterol ≥ 130 mg/dL) * Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week * Willing and able to participate in all aspects of the individual and household-level intervention * Fluent in written and spoken English Exclusion Criteria: * No children * Pregnancy * Serious illness such as cancer or chronic pain that may contraindicate full participation
Conditions Hypertension
Phase NA
Enrollment 261
Locations 51 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with uncontrolled hypertension (HTN) receiving 0 - 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving 1 - 2 anti-hypertensive drugs of different classes and who accept to be off-medications for a 4-week wash-out period before RDN/Sham procedure and 2 months after the procedure

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: TIVUS™ Renal Denervation System — Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
  • Other: Sham — For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.

Primary Outcomes

  • Reduction in average daytime ambulatory systolic BP (From baseline to 2 months post-procedure)
  • Subject level composite of the incidence of Major Adverse Events (MAE) (From Baseline to 30 day and 6 months post procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-03
Completion: 2028-08-15
Eligibility
Age: 22 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 261 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SoniVie Inc.
Collaborators: NAMSA, European Cardiovascular Research Center, IQVIA Pty Ltd
Principal Investigators:
  • Ajay Kirtane, MD (STUDY_CHAIR) - Columbia University
  • Michel Azizi, MD (STUDY_CHAIR) - George Pompidou Hospital
  • Felix Mahfoud, MD (STUDY_CHAIR) - University of Basel
Contact Information
Study Contact:
Lisa Melchior
651-324-4931
lisa.melchior@bsci.com
Janelle Noble
612-598-4368
janelle.noble@bsci.com
Susan DeRamus
SDeRamus@cardiologypc.com
Cardiology, PC
Interventions
  • Device: TIVUS™ Renal Denervation System — Renal artery catheterization procedure used to denervate the renal sympathetic nerves in the perivascular space using ultrasound energy.
  • Other: Sham — For those subjects randomized to the sham control, the angiogram will serve as the sham procedure.
Study Locations (51 sites)
Cardiology, PC, Birmingham, Alabama 35211 United States
HonorHealth, Scottsdale, Arizona 85258 United States
St. Bernard's Medical Center, Jonesboro, Arkansas 72401 United States
Arkansas Heart Hospital, Little Rock, Arkansas 72211 United States
Cedar-Sinai Medical Center, Los Angeles, California 90048 United States
Stanford University, Palo Alto, California 94305 United States
Connecticut Clinical Research, LLC (Bridgeport), Bridgeport, Connecticut 06610 United States
Ascension- Sacred Heart, Pensacola, Florida 32504 United States
Baycare Health System, Safety Harbor, Florida 34695 United States
University of South Florida, Tampa, Florida 33606 United States
Eligibility Criteria
Inclusion Criteria: 1. Appropriately signed and dated informed consent 2. Male and female adults with age between ≥22 and ≤75 years at time of consent 3. Documented history of hypertension 4. Previously or currently prescribed antihypertensive therapy 5. Subject has an office BP (average of 3 seated measurements) of: 1. Uncontrolled BP: ≥ 140/90 mmHg \<180/110 mmHg at Screening Visit (V0) while stable for at least 4 weeks on 0-2 anti-hypertensive medications of different classes\* and willing to stop anti-hypertensive medication(s) for 4 weeks wash-out and 2-months post-procedure, (subjects with a history of treatment with anti-hypertensive medications but are not currently taking any at screening will undergo a 4-week run-in period) or, 2. Controlled BP: \< 140/90 mmHg while stable for at least 4 weeks on 1-2 antihypertensive medications of different classes and willing to stop anti-hypertensive medication(s) for 4 weeks wash-out and 2-months post-procedure 6. Able and willing to comply with all study procedures 7. Subject is willing to have and is a good candidate for conscious sedation Subjects who meet the following criteria will be considered eligible for randomization: * Documented daytime systolic ABP ≥ 135 mmHg and \< 180 mmHg after 4-week washout/run-in period.\*\* * Suitable renal anatomy compatible with the renal denervation procedure, documented by renal CTA or MRA of good quality performed within one year prior to consent (a CTA or MRA will be obtained in subjects without a recent (≤1 year) cross-sectional renal imaging). The renal angiogram procedure done in the cath lab prior to randomization will serve as the final anatomy compatibility check. * Potassium-sparing diuretics such as Amiloride hydrochloride and Triamterene may be prescribed in combination with another diuretic (e.g. a thiazide or loop diuretic) for their potassium conservation properties. In this situation, the diuretic combination is considered as a single class of anti-hypertensive. Exclusion Criteria: 1. Subject has been previously diagnosed with abnormal renal artery anatomy and/or renal anatomy such as a single kidney, ectopic or horseshoe kidney, polycystic kidney disease, kidney tumors or other findings precluding renal denervation therapy as detailed in the angiographic exclusion criteria 2. Uncorrected causes of secondary hypertension other than sleep apnea (including, but not limited to): aldosteronism, renal parenchymal disease, renovascular disease, excess catecholamines, Cushing's syndrome, erythropoietin use, pheochromocytoma, hypo/hyperthyroidism, hyperparathyroidism, acromegaly) 3. Type I diabetes mellitus or uncontrolled Type II diabetes (defined as a plasma HbA1c ≥ 9.0%) 4. eGFR of \<40 mL/min/1.73 m2 CKD-EPI as calculated using the CKD-EPI 2021 equation 5. Cerebrovascular event (e.g. stroke, transient ischemic event, cerebrovascular accident) within 6 months prior to consent 6. History of severe cardiovascular event (e.g. myocardial infarction, unstable angina, CABG, acute heart failure requiring hospitalization (NYHA III-IV) within 12 months prior to consent 7. Subject has severe valvular stenosis or insufficiency 8. Documented repeat (\>1) hospitalization for hypertensive crisis within the prior 12 months and/or any hospitalization for hypertensive crisis within three (3) months prior to consent 9. Prescribed to any standard antihypertensive cardiovascular medication (e.g. beta blockers) for other chronic conditions (e.g. ischemic heart disease) such that discontinuation might pose serious risk to health in the opinion of the investigator 10. Subject with rapid, uncontrolled, symptomatic atrial fibrillation 11. Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal stimulator; baroreflex stimulator) 12. Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea. 13. Subject has a planned major surgery (any procedure requiring general anesthesia) in the next 12 months. 14. Subject on anticoagulant therapy that cannot be temporarily withheld for study procedure. 15. Primary pulmonary hypertension 16. Documented contraindication or allergy to contrast medium not amenable to treatment 17. Limited life expectancy of \< 1 year at the discretion of the Investigator 18. Night shift worker 19. Subject has frequent intermittent or chronic pain that results in treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for two or more days per week over the month prior to enrollment. 20. Subject is taking immunosuppressive therapy for diseases featuring vasculitis 21. Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders 22. Pregnant, nursing or planning to become pregnant within 12 months post procedure. Negative pregnancy test required, documented within a maximum of 7 days prior to procedure for all women of childbearing potential. Documentation of effective contraception is also required for women of childbearing potential 23. Subject has a planned major surgery or cardiovascular intervention in the next 6 months 24. Subject with history of renal transplantation 25. Evidence of active infection within 7 days of procedure (based on positive lab test and requiring therapy). 26. Subject has hypertrophic cardiomyopathy or amyloidosis. 27. Prior renal denervation procedure 28. Concurrent enrollment in any other investigational drug or device trial (participation in non-interventional studies/registries is acceptable) 29. Subject on a beta blocker for a condition other than antihypertension Angiographic Exclusion Criteria: The following characteristics identified either on the renal artery CT scan or MRI or on the Eligibility II Renal artery Angiogram will prevent the subject from being included: 1. Main renal arteries lumen diameter \< 4 mm. 2. Main renal treatable artery length \<20mm (may include proximal branching). 3. Accessory renal arteries that supplies ≥ 25% of the parenchyma, and \< 4 mm in lumen diameter. 4. Aorto-renal angle that prevents a safe cannulation of the renal artery. 5. Severe common femoral artery, common and/or external iliac artery, renal, iliac or aortic calcification or tortuosity that may compromise the safe performance and completion of the TIVUS™ procedure. 6. Hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which, would interfere with safe cannulation of the renal artery or meets local standards for surgical repair or interventional dilation (NOTE: vessel areas with calcification and fibromuscular dysplasia (FMD) should be avoided as intended treatment areas). 7. Any renal artery stenosis \> 30% by visual assessment. 8. Any renal artery aneurysm (\>50% of the main renal artery reference vessel diameter by visual estimate). 9. Presence of fibromuscular dysplasia of the renal arteries 10. Significant renal artery atheroma, aneurysm, calcification in the target vessel identified on CT Angiogram
Conditions TIPS, Portal Hypertension, Porto-Sinusoi...
Phase Not Applicable
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related. The study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Primary Outcomes

  • overall survival after TIPS placement (at 3 months)
  • overall survival after TIPS placement (at 6 months)
  • overall survival after TIPS placement (at 1 year)
  • overall survival after TIPS placement (at 2 years)
  • overall survival after TIPS placement (at 3 years)
  • overall survival after TIPS placement (at 4 years)
  • overall survival after TIPS placement (at 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-05-16
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire, Amiens
Collaborators: Groupe Hospitalier Pitie-Salpetriere, Rennes University Hospital, AP-HP - HU BEAUJON, University Hospital, Toulouse, CHRU TOURS, Centre Hospitalier Universitaire de Besancon, Hospices Civils de Lyon, France, APHP - HOPITAL AVICENNE, University Hospital, Montpellier, Saint-Luc University Hospital, CHU Poitiers, Centre Hospitalier Universitaire de Nice, CH HENRI MONDOR, Saint Antoine University Hospital, University Hospital, Rouen, Hopital Paul Brousse, Nantes University Hospital, Centre Hospitalier Universitaire Dijon, University Hospital, Bordeaux, University Hospital, Brest, University Hospital, Clermont-Ferrand
Contact Information
Study Contact:
Eric NGUYEN-KHAC, Pr
33+3 22 08 88 51
nguyen-khac.eric@chu-amiens.fr
Eric NGUYEN KHAC, PhD
+33322668883
nguyen-khac.eric@chu-amiens.fr
CHU Amiens Picardie
Marika Rudler, MD
CHU Amiens Picardie
Interventions
N/A
Study Locations (1 sites)
CHU Amiens Picardie, Amiens, Picardie 80054 France
Eligibility Criteria
Inclusion Criteria: * PSVD group : * Patient with PSVD according VALDIG criteria * TIPS for digestive hemorrhage on portal hypertension * TIPS for refractory ascite * TIPS for portal vein thrombosis * Cirrhosis group with PH : (appaired by age, sexe, type of PH complications) * Confirmed cirrhosis with : * TIPS for digestive hemorrhage on portal hypertension * TIPS for refractory ascite * TIPS for portal vein thrombosis Exclusion Criteria: * no PSVD confirmed diagnosis * Budd Chiari syndrome * Rendu Osler disease; Heart failure * Fontan; Sarcoïdosis * Schistosomiase * Congenitale liver fibrosis * Abernathy syndrome * Tumor infiltration by lymphoma * Bone graft
Conditions Diabetes Mellitus, Type 2, Hypertension,...
Phase NA
Enrollment 3772
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The Chronic Disease Co-Care (CDCC) Pilot Scheme is initiated for early screening and management of people with hypertension (HT), pre-diabetes mellitus (pre-DM) and diabetes mellitus (DM) in Hong Kong. This study will evaluate the quality of care, feasibility, acceptability, effectiveness and cost-effectiveness of the Scheme. This is a 12-month cohort study among the District Health Centre (DHC) or DHC Express, healthcare providers, CDCC participants and a comparison group of 1,886 non-participants. All the person-in charge, 2 family doctors and 1 of each allied health provider from each DHC/DHC Express will be administered with the questionnaires on quality of care and costing. All CDCC participants will be included in subject characteristics, among which a convenience sample of 548 will complete a telephone survey on experience, enablement and satisfaction of the CDCC Pilot Scheme. The health outcomes of 1,886 CDCC participants and 1,886 non-participants will be compared for evaluation of effectiveness and cost-effectiveness. Participant characteristics, enablement, compliance to the standards of care, and costing of CDCC Pilot Scheme will be summarized using descriptive statistics. Differences in the proportion of patients meeting treatment targeted for HT, pre-DM and DM after 12 months will be compared by chi-squared test and logistic regressions. The incremental cost-effectiveness ratio will be evaluated by comparing with the World Health Organization (WHO) threshold. This study will inform future healthcare planning and policy for manpower and resource allocation.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Combination Product: The Chronic Disease Co-Care (CDCC) Pilot Scheme — Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.

Primary Outcomes

  • Characteristics of the Chronic Disease Co-Care (CDCC) participants (Characteristics of CDCC participants will be described at baseline)
  • Healthcare providers' adherence to care standards on the evaluation framework by the quality of care questionnaire (Questionnaires will be implemented at 6 months and 12 months after the study begins)
  • Enablement of CDCC participants by the Chinese Patient Enablement Instrument (12 months)
  • Effectiveness of the CDCC Pilot Scheme on disease control for pre-diabetes mellitus (pre-DM) and DM in percent of Glycated Hemoglobin (HbA1c) and hypertension (HT) in millimeter of mercury of systolic blood pressure (SBP)/diastolic blood pressure (DBP) (12 months)
  • The additional costs for delivering the CDCC Pilot Scheme by the costing questionnaire (12 months)
  • The cost-effectiveness for delivering the CDCC Pilot Scheme on the incremental cost-effectiveness ratio (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-18
Completion: 2026-12-31
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: true
Enrollment: 3772 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Collaborators: Health and Medical Research Fund, Primary Healthcare Office, Hong Kong
Contact Information
Study Contact:
Eric Yuk Fai Wan
852 2831 5057
yfwan@hku.hk
Eric Yuk Fai Wan
852 28315057
yfwan@hku.hk
Jockey Club Building for Interdisciplinary Research 5 Sassoon Road, Pok Fu Lam, HONG KONG
Interventions
  • Combination Product: The Chronic Disease Co-Care (CDCC) Pilot Scheme — Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
Study Locations (1 sites)
Jockey Club Building for Interdisciplinary Research 5 Sassoon Road, Pok Fu Lam, HONG KONG, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria of interventional group: * Hong Kong residents * Aged ≥45 years * Registered as a member of DHC/DHC Express * Provided informed consent on sharing their data in the electronic Health Record Sharing System * Provided consent to join the CDCC Pilot Scheme Terms and Conditions. Exclusion Criteria of interventional group: * With known history of DM or HT Inclusion Criteria of comparison group: * Hong Kong residents * Aged ≥45 years * Provided informed consent for the study. Exclusion Criteria of comparison group: * Without known history of DM or HT
Conditions Blood Pressure Control
Phase NA
Enrollment 4
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The vast majority of the 36.2 million individuals admitted to U.S. hospitals are diagnosed with hypertension and experience an elevated blood pressure (BP) reading during hospitalization. There are no guidelines for managing asymptomatically elevated BPs in the inpatient setting, and growing observational evidence suggests that antihypertensive medication intensification increases harm. The proposed study tests whether a unit-based intervention (ACT-BP) can reduce antihypertensive medication intensification and provides information that is scientifically necessary for designing a cluster-randomized clinical trial that identifies the impact of intensification after experiencing an asymptomatically elevated BP on patient outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: ACT-BP Intervention — In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.

Primary Outcomes

  • Primary Outcome (From date of first elevated BP reading until the end of hospitalization, assessed up to 13 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-11
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 4 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Elizabeth Pfoh
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Elizabeth Pfoh, PhD, MPH (PRINCIPAL_INVESTIGATOR) - The Cleveland Clinic
Contact Information
Study Contact:
Elizabeth Pfoh, PhD, MPH
12162963034
pfohe@ccf.org
Emma J Wensink
216-442-5341
wensine2@ccf.org
Cleveland Clinic Main Campus
Elizabeth Pfoh
Cleveland Clinic Main Campus
Interventions
  • Other: ACT-BP Intervention — In our intervention units, the study team will change the unit-based protocols to follow the ACT-BP intervention. First, it prompts the nurse to identify if a patient is experiencing hypertensive emergencies or cardiac symptoms. If so, it suggests calling the physician. If not, it prompts assessment for pain, anxiety, nausea, or hunger and provides evidence-based suggestions. It also prompts monitoring to enhance patients' safety in the case of rapidly rising BP. This algorithm will provide a path for ensuring patients receive appropriate treatment.
Study Locations (2 sites)
Cleveland Clinic Main Campus, Cleveland, Ohio 44195 United States
Cleveland Clinic Hillcrest, Mayfield Heights, Ohio 44124 United States
Eligibility Criteria
Inclusion Criteria: * At the unit level: Medical units that do not typically care for patients requiring step-down care. Exclusion Criteria: 1. Patients less than 18 2. Patients experiencing hypertensive emergencies or cardiac symptoms 3. Patients with active cardiovascular events, such as * Stroke * Non-ST-elevation * Myocardial infarction * End-stage renal disease * Patients on dialysis * Those with acute decompensated heart failure 3\. Patients on the unit for more than 10 days 4\. Patients transferred in after being in the intensive care unit (ICU) 5\. Pregnant and post-partum women 6\. Patients discharged within 24 hours of admission 7\. Patients whose systolic BP remains below 160 mmHg during hospitalization.